Background {#Sec1}
==========

Fluoroquinolones (FQs) are effective antimicrobial agents by directly inhibiting the process of bacterial DNA synthesis. With the broad-spectrum antibacterial coverage, they are widely used in bacterial infections, like acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and uncomplicated urinary tract infections for adults. In addition to the strength of broad-spectrum antibacterial coverage, other advantages, such as high oral bioavailability, large volume of distribution, ideal tissue penetration and long-lasting medicine, make FQs a favorable choice in treating infectious diseases \[[@CR1], [@CR2]\].

However, FQs are not the first choice in clinical guideline for treating infectious diseases, since they have been reported to be associated with collagen degradation, which may lead to severe and detrimental adverse effects like tendon ruptures, retinal detachments, gastrointestinal tract perforation, even aortic aneurysms in adults \[[@CR3]--[@CR7]\]. FQs were previously found to cause apoptotic changes in extracellular matrix and significantly decrease collagen type I and the β1-integrin receptors \[[@CR8]\]. Collagen defects-related tissue damages are found not only in tendons, but also tissues composed of collagen, such as aortic wall, gastrointestinal (GI) tract, and retina \[[@CR5], [@CR9], [@CR10]\]. All of these findings attribute to the cause of collagen-associated adverse effects. To alarm the risks of adverse effects of FQs, the U.S. FDA declared several warnings containing potential tendinitis, tendon ruptures, and even irreversible peripheral neuropathy \[[@CR11], [@CR12]\].

On the other hand, the original toxicological studies with quinolones documented the cartilage injury in weight-bearing joints in canine puppies \[[@CR13]\]. With the concern of potential negative impacts on musculoskeletal development in growing children, systemically administered FQs are not recommended for routine use in children younger than18 years old except for some complicated and complex infectious diseases cases \[[@CR14]\]. To follow the clinical guidelines and recommendations in treating infectious diseases in children \[[@CR15]\], the physicians tend to reserve the prescriptions of FQs as the last line antibiotics to tackle with fulminant and invasive bacterial infections at hospitals in Taiwan.

Although the use of FQs to treat bacterial infection in pediatric population has been decreasing with time, there is still a small pediatric group who needs FQs for treating serious and multiple drug-resistant bacterial infections rising in the community \[[@CR16], [@CR17]\]. For this reason, it is urgently needed to evaluate the safety of FQs in clinical use. After reviewing the literatures, we found that most of the study subjects for adverse effects of FQs were older than 18-year old patients \[[@CR3]--[@CR5], [@CR7], [@CR18]\]. By contrast, there are still a few publications reporting benefits for using FQs in children \[[@CR19], [@CR20]\]. Since the lack of sufficient evidence-based articles found in pediatric population, the purpose of our study is to investigate the safety issue of FQs-induced collagen-associated adverse effects at the young age group.

Methods {#Sec2}
=======

Data sources {#Sec3}
------------

We performed a cohort study by using the National Health Insurance Research Database (NHIRD) of Taiwan. The National Health Insurance (NHI) system of Taiwan covers more than 99.6% of the Taiwanese population \[[@CR21]\]. This database is representative of the population in Taiwan, and always used in generating evidence to support clinical decisions or healthcare policy-making \[[@CR22]\]. All data from primary outpatient departments and inpatient hospital care settings after year 2000 were included in this database. This longitudinal health insurance database in year 2000--2013 in Taiwan was collected by randomly selecting individuals from the registry for beneficiaries of the NHI program. It contains complete outpatient and inpatient electronic claim records, individual diagnoses, procedures, and medicine prescription. This database is commonly used in several population-based studies and pharmacoepidemiologic research in Taiwan. (<https://nhird.nhri.org.tw/>).

Medication exposure {#Sec4}
-------------------

In this study, medication exposure was defined as receiving FQs in either oral or intravenous form of the following active compounds including ciprofloxacin, levofloxacin, ofloxacin, gemifloxacin, norfloxacin, and moxifloxacin. Topical or external form of prescription was not included. The prescription period was equal to (or longer than) five consecutive days to correspond with the inclusion criteria.

Inclusion and exclusion criteria {#Sec5}
--------------------------------

We utilized data between year 2000 and 2013 from NHIRD of a sub-dataset, longitudinal health insurance database (*n* = 989,753). All patients aged 0\~18 years old with FQs prescriptions ≥5 consecutive days after January 1, 2000 were selected and included into this cohort. The total cases were 33,537 individuals included. The patients without tracking information (*n* = 22), with missing data on gender (*n* = 7), those who ever received FQs before index date (*n* = 65), with collagen-associated adverse events, and primary or secondary collagen diseases prior to enrollment (*n* = 4) were excluded. Also, we excluded cases with the diagnosis of appendicitis (International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM code): 540--543), peritonitis (ICD-9-CM code: 567), and typhoid fever (ICD-9-CM code: 002) (*n* = 18) because the symptoms of these diseases are similar to one of the primary outcomes (GI perforation) in this study \[[@CR4]\]. The total excluded cases were 116 individuals. Overall, the final enrolled cases with the use of FQs were 33,421 individuals. Propensity score matching was used for selecting control group, and 4-fold case number were selected (Fig. [1](#Fig1){ref-type="fig"}). Fig. 1The flowchart of study sample selections

Outcome {#Sec6}
-------

All of the diseases and adverse effects were defined by ICD-9-CM. The outcome was evaluated and defined by the newly diagnosis of the collagen-associated adverse events, including tendons rupture (727.6), retinal detachments (361.0), gastric perforation (531.1, 531.2, 531.5, 531.6, 532.1, 532.2, 532.5, 532.6, 533.1, 533.2, 533.5, 533.6, 534.1, 534.2, 534.5, and 534.6), small or large intestinal perforation (569.83) \[[@CR4]\], aortic aneurysm (441.1, 441.2, 441.3, 441.4, 441.5, 441.6, 441.7, and 441.9), and aortic dissection (441.0, 441.00, 441.01, 441.02, and 441.03) \[[@CR18]\].

Covariates {#Sec7}
----------

In order to be as comprehensive as possible in adjusting for factors that might confound the studied association, we identified several covariates such as catastrophic illness to adjust the baseline health conditions of selected patients, and low-income household for individual financial conditions. On the other hand, medicine such as nonsteroidal anti-inflammatory drugs (NSAIDs) and steroid are both well-known for causing gastrointestinal mucosal damage \[[@CR23], [@CR24]\]. Since these two medicines were commonly used in our study population, we added these two items as covariates to eliminate the interference of outcome interpretation. Moreover, we also adjusted for selected other variables such as seasons, levels of urbanization, healthcare, and comorbidities (including cerebrovascular accident, diabetes Mellitus, hypertension, hyperlipidemia) \[[@CR25]--[@CR27]\] for minimizing potential biases.

Statistical analysis {#Sec8}
--------------------

Statistical analyses were performed using Chi-square/Fisher exact test on category variables and t-test on continuous variables. Characteristics and outcome events of cohort patients for the FQs and FQs free groups were reported as number and percentage, mean and standard deviation, as appropriate. The Kaplan--Meier analysis and log-rank test were used for calculating the cumulative incidence rates of collagen-associated adverse events between FQs group and FQs-free group. The multivariable Cox proportional hazard model was used to estimate the hazard ratio (HR) of collagen-associated adverse events associated with the use of FQs. Our definition of significant level was 0.05 to detect differences in collagen-associated adverse events between FQs group and FQs-free group. All analyses were performed with SPSS version 22.

Results {#Sec9}
=======

This study involved a total of 33,421 for the FQs group and 133,684 for the FQs free controls. Of the enrolled patients (*n* = 167,105), collagen-associate adverse effects developed in 85 (0.051%) in 6-month tracking, including 0.051% in the FQs study cohort (17 in 33,421) and 0.051% (68 in 133,684) in the FQs-free comparison cohort.

Baseline characteristics of patients {#Sec10}
------------------------------------

Baseline characteristics of case patients and comparators are listed in the Table [1](#Tab1){ref-type="table"}. There were no significant differences between the FQs group and FQ-free group in the distributions of age and sex, but the proportion of catastrophic illness was slightly higher in the FQs group than the FQs-free groups (0.6 vs. 0.38). Table 1Characteristics of studyFluoroquinolonesTotalWithWithout*P*Variablesn%n%n%Total167,10533,42120.00133,68480.00Collagen-associated adverse events0.990 Without167,02099.9533,40499.95133,61699.95 With850.05170.05680.05Collagen-associated adverse events subgroups0.990 Without167,02099.9533,40499.95133,61699.95 Tendons rupture00.0000.0000.00 Retinal detachments00.0000.0000.00 Gastrointestinal perforation850.05170.05680.05 Aortic dissection/Aortic aneurysm00.0000.0000.00Gender0.999 Male85,99051.4617,19851.4668,79251.46 Female81,11548.5416,22348.5464,89248.54Age (years)9.78 ± 5.589.83 ± 5.359.77 ± 5.630.079Age group (years)0.999 \< 151003.0510203.0540803.05 171454.2814294.2857164.28 279704.7715944.7763764.77 390605.4218125.4272485.42 410,6806.3921366.3985446.39 5--946,67027.93933427.9337,33627.93 10--1442,78525.60855725.6034,22825.60 ≧1537,69522.56753922.5630,15622.56Catastrophic illness\< 0.001 Without166,39899.5833,22299.40133,17699.62 With7070.421990.605080.38Low-income household\< 0.001 Without164,08998.2032,56197.43131,52898.39 With30161.808602.5721561.61Season\< 0.001 Spring (Mar - May)43,86726.25875726.2035,11026.26 Summer (Jun - Aug)42,83625.63843525.2434,40125.73 Autumn (Sep - Nov)41,28724.71828924.8032,99824.68 Winter (Dec - Feb)39,11523.41794023.7631,17523.32Urbanization level\< 0.001 1 (the highest)45,24027.07734321.9737,89728.35 262,22237.2411,92935.6950,29337.62 327,98016.74643319.2521,54716.12 4 (the lowest)31,66318.95771623.0923,94717.91Level of care\< 0.001 Hospital center75594.5212683.7962914.71 Regional hospital11,8587.1019395.8099197.42 Local hospital87625.4915884.9471745.63 Physician clinics138,92683.1428,62685.65110,30082.51Comorbidities Cerebrovascular accident430.0380.02350.030.819 Diabetes mellitus840.05180.05660.050.743 Hypertension960.06200.06760.060.838 Hyperlipidemia740.04150.04590.040.954Drugs Non-steroidal anti-inflammatory drugs50083.0010233.0639852.980.443 Systemic steroid9150.551880.567270.540.679*P:* Chi-square / Fisher exact test on category variables and t-test on continue variables

Collagen-associated adverse events {#Sec11}
----------------------------------

In the cohort, we did not observe any case of tendons rupture, retinal detachments, aortic aneurysms, and aortic dissection. Patients with collagen-associated adverse events (GI perforation) in FQs group included 1 individual in 7-day tracking, 3 individuals in 14-days tracking, 4 individuals in 28-days tracking, 12 individuals in 3-month tracking, and 17 individuals in 6-month tracking. However, patients with collagen-associated adverse events (GI perforation) in FQs free group were 2 individuals in 3-days tracking, 6 individuals in 7-days tracking, 10 individuals in 14-days tracking, 14 individuals in 28-days tracking, 45 individuals in 3-month tracking, 68 individuals in 6-month tracking (Fig. [1](#Fig1){ref-type="fig"}). The crude HR for collagen-associated adverse events in FQs group was 0.997 (95% CIs; 0.586--1.696; *p* = 0.990) (Table [2](#Tab2){ref-type="table"}). Table 2Factors of gastrointestinal perforation in 6-month tracking by using Cox regressionVariablesCrude HR95% CI95% CI*P*Adjusted HR95% CI95% CI*P*Adjusted HR95% CI95% CI*P*Fluoroquinolones WithoutReferenceReferenceReference With0.9970.5861.6960.9901.3290.7762.2740.2571.3300.7782.2760.255Gender Male1.1530.7531.7640.5131.0400.7911.3400.0621.0330.8091.3820.064 FemaleReferenceReferenceReferenceAge (years)0.9760.9391.0140.2140.9680.9311.0060.094Age group (years) \< 1ReferenceReference 11.8350.7084.7560.2122.0470.7845.3450.123 20.6200.1062.2900.4730.6690.8102.4880.556 31.8020.7154.5400.2121.8220.7524.6480.189 40.3680.0791.7030.2010.3810.8801.7780.225 5--90.4410.1931.0080.0520.4330.1790.9520.040 10--140.4150.1770.9710.0430.3860.1630.9090.028 ≧150.9440.4422.0140.8810.8310.3841.7890.661Catastrophic illness WithoutReferenceReferenceReference With5.9720.014161.7820.9852.7400.29213.4210.9282.7390.29113.4110.938Low-income household WithoutReferenceReferenceReference With1.6430.0904.6200.6611.5460.0764.1050.5781.5410.0724.0700.572Season SpringReferenceReferenceReference Summer0.2180.1270.377\< 0.0010.2090.1210.362\< 0.0010.0220.1260.374\< 0.001 Autumn0.0170.0060.047\< 0.0010.0180.0060.048\< 0.0010.0170.0070.050\< 0.001 Winter0.0560.0320.098\< 0.0010.0570.0320.099\< 0.0010.0570.0320.100\< 0.001Urbanization level 1 (the highest)1.9931.0323.8490.0402.0341.0334.0020.0332.0431.0314.0240.029 20.5960.2761.2880.1880.5260.2391.1440.1150.5270.2421.1460.116 32.3571.1844.6910.0152.5811.2945.1460.0032.5861.2945.1530.006 4 (the lowest)ReferenceReferenceReferenceLevel of care Hospital center2.9091.2326.8710.0152.7681.1326.7590.0142.7571.1246.7340.010 Regional hospital7.6134.60812.579\< 0.0018.3515.00813.884\< 0.0018.4805.02914.208\< 0.001 Local hospital6.2133.42511.269\< 0.0015.3042.9119.672\< 0.0015.2222.8649.526\< 0.001 Physician clinicsReferenceReferenceReferenceComorbidities (No reference) Cerebrovascular accident10.4540.02225.1240.9865.1310.00916.7520.9925.1040.00916.6410.992 Diabetes mellitus3.4010.5646.7850.2983.1050.4826.1310.3843.0780.4766.0790.390 Hypertension1.8980.6753.9960.7441.7760.6033.2970.7561.6230.5983.1110.758 Hyperlipidemia0.000----0.9890.000----0.9970.000----0.997Drugs (No reference) NSAID1.2640.8421.6770.5621.1890.6751.5970.5991.1870.6731.5890.598 Systemic steroid1.1010.7651.2970.4381.0860.5671.2730.5011.0850.5611.2700.497*HR* Hazard ratio, *CI* Confidence interval, *Adjusted HR* Adjusted variables listed in the table, *NSAID* Non-steroidal anti-inflammatory drugs

Risk of collagen-associated adverse events {#Sec12}
------------------------------------------

After adjusting for age, sex, catastrophic illness, low-income household, seasons, levels of urbanization and healthcare, the adjusted HR for collagen-associated adverse events in FQs group was 1.330 (95% CI; 0.778--2.276; *p* = 0.255). After multivariate analysis, we noticed that patient's age was associated with the risk of GI perforation. As shown in Table [2](#Tab2){ref-type="table"}, the risk of collagen-associate adverse effect was lower in patients aged 5\~9 years old (aHR = 0.433; 95% CIs = 0.179--0.952; *p* = 0.040), patients aged 10\~14 years old (aHR = 0.386; 95% CI = 0.163--0.909; *p* = 0.028).

Subgroup analyses {#Sec13}
-----------------

The association of FQs with subsequent GI perforation was stratified by baseline demographic, catastrophic illness, low-income household, seasons, levels of urbanization and healthcare. Analyses of factors of GI perforation in 6-month tracking stratified by the aforementioned variables were performed by Cox regression as shown in Table [3](#Tab3){ref-type="table"}. We did not observe any statistically significant difference between FQs group and FQs-free group after subgroup analyses of gender, age, catastrophic illness, low-income household, seasons, levels of urbanization and healthcare. Table 3Factors of gastrointestinal perforation in 6-month tracking stratified by variables listed in the table by using Cox regressionFluoroquinolonesWithWithoutRatioWith vs. WithoutStratifiedEventsPDsRate (per 10^5^ PDs)EventsPDsRate (per 10^5^ PDs)Adjusted HR95% CI95% CI*P*Total175,940,776.060.296823,707,602.750.290.9981.3300.7782.2760.255Gender Male103,060,435.000.333112,297,000.620.251.2961.7440.9212.9830.643 Female72,880,341.060.243711,410,602.120.320.7491.0080.5561.7240.297Age group (years) \< 11183,600.000.544820,422.120.491.1171.5030.8762.5720.675 12256,265.940.783876,927.190.342.2812.2790.9984.0270.052 21286,506.190.3541,024,530.500.390.8941.1940.7021.9600.536 32325,930.750.6151,282,879.440.391.5741.8220.9432.8940.071 41384,465.190.2661,542,322.120.390.6690.8990.5251.2750.489 5--931,677,499.810.18146,622,008.940.210.8461.1390.6691.9490.376 10--1421,521,852.940.13106,123,547.690.160.8051.0800.6351.8510.447 ≧1551,304,655.250.38225,414,964.750.410.9431.2710.7422.1700.285Catastrophic illness Without165,907,063.870.276823,616,531.120.290.9411.2640.7352.1630.194 With133,712.192.97091,071.620.00∞∞----0.796Low-income household Without165,789,090.440.286823,320,517.250.290.9481.2770.7442.1830.182 With1151,685.620.660387,085.500.00∞∞----0.785Season Spring51,209,564.810.41236,731,139.190.341.2101.6280.9522.7920.073 Summer31,211,624.370.25125,549,493.380.221.1451.5390.9012.6390.102 Autumn21,596,290.690.13105,377,612.870.190.6740.9070.5241.5510.773 Winter71,923,296.190.36236,049,357.310.380.9571.2880.7512.2040.288Urbanization level 1 (the highest)61,305,977.190.46306,700,633.870.451.0261.3780.8082.3640.134 222,119,226.310.09128,911,079.560.130.7010.9420.5531.6160.446 371,142,905.310.61193,835,392.810.501.2361.6630.9712.8430.059 4 (the lowest)21,372,667.250.1574,260,496.500.160.8871.1850.6922.0410.334Level of care Hospital center6222,455.872.70261,083,958.872.401.1241.1560.8842.5880.240 Regional hospital5343,936.381.45191,737,590.941.091.3291.7940.9723.0590.062 Local hospital4281,046.941.42151,249,182.121.201.1851.5890.9322.7350.179 Physician clinics25,093,336.870.04819,636,870.810.040.9641.2900.7592.2140.304*PDs* Person-days, *Adjusted HR* Adjusted Hazard ratio: Adjusted for the variables listed in Table [2](#Tab2){ref-type="table"}, *CI* Confidence interval

Stratified by fluoroquinolones {#Sec14}
------------------------------

Also, we did the subgroup analysis to confirm the association of FQs subgroup with subsequent GI perforation in different tracking periods by using Cox regression. In 3-day tracking period, we observed 2 events from FQs-free group. In 7-day tracking period, we observed 1 event from ofloxacin in the FQs group, and 6 events from FQs-free group. In 14-day tracking period, we observed 1 event from ciprofloxacin, 1 event from norfloxacin, and 1 event from ofloxacin in the FQs group, and 10 events from FQs-free group. In 28-day tracking period, we observed 1 event from ciprofloxacin, 1 event from norfloxacin, 2 events from ofloxacin in the FQs group, and 14 events from FQs-free group. In 3-month tracking period, we observed 1 event from ciprofloxacin, 3 events from norfloxacin, and 8 events from ofloxacin in the FQs group, and 45 events from FQs-free group. In 6-month tracking period, we observed 1 event from ciprofloxacin, 3 events from norfloxacin, and 13 events from ofloxacin in the FQs group, and 68 events from FQs-free group. The incidence rate and adjusted HR are listed in Table [4](#Tab4){ref-type="table"}. None of them were statistically significant difference between FQs group and FQs-free group. Table 4Factors of gastrointestinal perforation stratified by fluoroquinolones subgroup in different tracking period by using Cox regressionTracking periodFluoroquinolones subgroupPopulationsEventsPDsRate (per 10^5^ PDs)Adjusted HR95% CI95% CI*P*Adjusted HR95% CI95% CI*P*3-dayWithout133,684223,707,602.750.01ReferenceReferenceWith33,42105,940,776.060.000.000----0.995 Levofloxacin6530112,735.690.000.000----0.960 Ciprofloxaxin18430316,411.560.000.000----0.978 Moxifloxacin139024,500.000.000.000----0.988 Gemifloxacin1202160.000.000.000----0.998 Norfloxacin704101,261,596.870.000.000----0.996 Ofloxacin23,73304,223,371.940.000.000----0.9907-dayWithout133,684623,707,602.750.03ReferenceReferenceWith33,42115,940,776.060.020.5120.08027.4260.756 Levofloxacin6530112,735.690.000.000----0.982 Ciprofloxaxin18430316,411.560.000.000----0.979 Moxifloxacin139024,500.000.000.000----0.993 Gemifloxacin1202160.000.000.000----0.986 Norfloxacin704101,261,596.870.000.000----0.978 Ofloxacin23,73314,223,371.940.020.7760.11472.3010.44214-dayWithout133,6841023,707,602.750.04ReferenceReferenceWith33,42135,940,776.060.051.0250.0441.3560.111 Levofloxacin6530112,735.690.000.000----0.986 Ciprofloxaxin18431316,411.560.321.5720.0527.1660.678 Moxifloxacin139024,500.000.000.000----0.995 Gemifloxacin1202160.000.000.000----0.986 Norfloxacin704111,261,596.870.081.3420.0206.9880.501 Ofloxacin23,73314,223,371.940.020.4270.0354.9720.49428-dayWithout133,6841423,707,602.750.06ReferenceReferenceWith33,42145,940,776.060.071.1370.0901.4980.157 Levofloxacin6530112,735.690.000.000----0.978 Ciprofloxaxin18431316,411.560.321.2660.0282.9990.267 Moxifloxacin139024,500.000.000.000----0.978 Gemifloxacin1202160.000.000.000----0.964 Norfloxacin704111,261,596.870.082.0520.18422.4850.532 Ofloxacin23,73324,223,371.940.050.3070.5551.7520.1883-monthWithout133,6844523,707,602.750.19ReferenceReferenceWith33,421125,940,776.060.201.0490.1561.9250.198 Levofloxacin6530112,735.690.000.000----0.952 Ciprofloxaxin18431316,411.560.321.0760.0131.9720.129 Moxifloxacin139024,500.000.000.000----0.978 Gemifloxacin1202160.000.000.000----0.986 Norfloxacin704131,261,596.870.241.4720.4025.4110.524 Ofloxacin23,73384,223,371.940.190.3900.1451.7860.3796-monthWithout133,6846823,707,602.750.29ReferenceReferenceWith33,421175,940,776.060.291.3300.7782.2760.255 Levofloxacin6530112,735.690.000.000----0.975 Ciprofloxaxin18431316,411.560.321.4020.19710.1210.702 Moxifloxacin139024,500.000.000.000----0.966 Gemifloxacin1202160.000.000.000----0.973 Norfloxacin704131,261,596.870.240.9110.3483.5260.813 Ofloxacin23,733134,223,371.940.311.4420.7932.6010.199*PDs* Person-days, *Adjusted HR* Adjusted hazard ratio: Adjusted for the variables listed in Table [2](#Tab2){ref-type="table"}, *CI* Confidence interval

Discussion {#Sec15}
==========

Fluoroquinolones are highly effective antimicrobial agents with the following advantages: a broad spectrum of bactericidal activity, ideal bioavailability, both oral and intravenous formulations, high serum levels and a large volume of distribution. These advantages increase the FQs usage in a wide variety of infectious diseases, including skin and respiratory infections for adults. However; the post-marketing surveillance data indicates that FQs may cause subsequent collagen-associated adverse events. Since year 2008, the U.S. FDA has declared several warnings about the association of FQs with disabling and potentially permanent side effects involving tendons, muscles, joints, nerves and the central nervous system in succession \[[@CR28]\]. Additionally, due to the toxic effects observed from juvenile animals treated with FQs, the use of FQ-related drugs became rather limited in pediatric population \[[@CR13]\]. Only ciprofloxacin and levofloxacin are approved by the U.S. FDA for the treatment of inhalation anthrax, complicated UTIs, and pyelonephritis in children aged 1 to 17 years old \[[@CR15]\]. Furthermore, with the overuse of antimicrobial agents in clinical practice, the emergence of antibiotic resistant bacteria is rising in Taiwan \[[@CR29]\]. To overcome the surge of drug resistant issues, the use of FQs is also increasing. To evaluate the safety issue of FQs, it is necessary for us to investigate serious collagen-associated adverse events in pediatric population.

The main findings of our study demonstrated that there was no difference in the risk of collagen-associated adverse events between FQs group and FQs-free group in pediatric population. By reviewing published studies \[[@CR3]--[@CR7], [@CR18]\], we noticed that the reported higher risk of collagen-associate adverse effect in FQs-related cases were found in patients at the age of over 18 years old. However, most of these studies were designed in case-control studies and the subjects were patients older than 18 years old \[[@CR3]--[@CR7], [@CR18]\]. After comparing the difference between our findings and previous reported results, we made the following to several explanations: (i)The study design: the subjects from case-control studies were identified by evaluating the outcome status at the outset of the investigation \[[@CR4], [@CR5], [@CR18]\]. Enrolled cases with the outcome of interest are matched with a control group without it. The major and inevitable problems in case-control studies are the sampling bias, observation bias and recall bias. In contrast, cohort studies are usually used to confirm the disease incidence, causes, and prognosis. Cohort studies are often utilized for measuring events in chronological order and clarifying the relationship between cause and effect \[[@CR30], [@CR31]\]. Consequently, we designed our study in the form of cohort study to assess the association between use of FQs and effect of collagen-associated adverse events. We believe that this cohort study provides more objective and reliable information than case-control studies.(ii)Dosage adjustment and rigorous monitoring in pediatric population: dosage of FQs is calculated and adjusted for by body weight in children before prescriptions. Maximum dosage limitation is advised by clinical guideline and FDA \[[@CR15]\]. Meanwhile, healthcare providers usually follow the recommendation strictly because of the concern of the adverse effects to this vulnerable population. Furthermore, physicians tend to avoid this class of antimicrobial agents in clinical practice and preserve them as the final therapy for difficult and serious bacterial infections. Therefore, the side effects become much less as expected attributing to precise dosage and strict indication.(iii)Comorbidity in elderly population: with regard to most of the FQs studies \[[@CR3]--[@CR7], [@CR18]\], the enrolled subjects were older than 18 years old, especially the elderly population with comorbidities, like cardiovascular diseases and diabetes \[[@CR32]\]. For example, cardiovascular diseases such as hypertension and hyperlipidemia, make the blood vessels more vulnerable and subsequently increase the risk of aortic aneurysms \[[@CR33]\]. Patients with diabetes have more problematic blood vessels and retinopathy, which increases the risk of retinal detachments \[[@CR34], [@CR35]\]. Thus, these underlying diseases may contribute to the side effects of FQs to some extent in elderly population, but they are less frequent in younger generation. These observative findings may partially explain why we found that pediatric patients in our cohort have less side effects compared with previous reports. Since these comorbidities were adjusted as the covariates in our study, we believe that these items won't be the confounding factors in this cohort.

Though our findings differ from the previous studies, we believe that it reflects the real clinical situations in pediatric population by meticulously analyzing the database resource in Taiwan. The National Health Insurance Research Database (NHIRD) of Taiwan, which covers more than 99.6% of the Taiwanese population, makes our study results more statistically powerful and representative \[[@CR21]\]. NHIRD has been also widely used in generating evidences to support clinical decisions or healthcare policy-making \[[@CR22]\].

Several limitations of the study should be noted. First, we are not sure about the compliance of the outpatient department patients because some of them may discontinue oral form of FQs abruptly \[[@CR36]\]. It may cause underestimation of the adverse effects of FQs because the patients did not complete the treatment course. According to the results from previous studies, up to 52.7% of subjects reported that they did not precisely follow the physicians' advice about antibiotics use \[[@CR37]\]. Second, the clinical conditions and underlying diseases of the enrolled cases during the observation period were not available. Underlying illness and chronic diseases may predispose to develop the collagen-associated adverse effects significantly. Third, no supportive image reports and laboratory data from each medical record to confirm the diagnosis of collagen-associated adverse effects, we defined the outcome in this study by reviewing the registration of ICD-9-CM codes. The potential misclassification bias cannot be ruled out in our study \[[@CR38]\]. Despite the potential limits, our study also has some strengths because the results of this study are based on a real-world database analysis. The enormous number of prescriptions records makes the results more reliable and unbiased. In addition, we tracked the patient's outcome up to 6 months to see the long-term impact of the FQs exposure.

Conclusions {#Sec16}
===========

We designed this population-based, retrospective cohort study to evaluate the safety of FQs in pediatric population in Taiwan. In this study, we did not observe any statistically significant difference in the incidence of collagen-associated adverse events between FQs group and FQs-free group. FQs use in pediatric patients seems safe under instruction on the basis of our findings. Therefore, the risk of collagen-associated adverse events in pediatric population may be overestimated in previous studies. Since physicians still need FQs to treat serious and fulminant bacterial infections in children, our data supports that physicians may prescribe FQs in seriously infected young patients as indicated in the guideline.

aHR

:   Adjusted hazard ratio

CI

:   Confidence interval

FQ

:   Fluoroquinolones

HR

:   Hazard ratio

ICD-9-CM

:   International Classification of Diseases, Ninth Revision, Clinical Modification

NHI

:   National Health Insurance

NHIRD

:   National Health Insurance Research Database

PDs

:   Person-days
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